Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $3.72 billion. The enterprise value is $6.12 billion.
Important Dates
The next estimated earnings date is Friday, May 1, 2026, before market open.
| Earnings Date | May 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMRX has 314.63 million shares outstanding. The number of shares has increased by 5.12% in one year.
| Current Share Class | 314.63M |
| Shares Outstanding | 314.63M |
| Shares Change (YoY) | +5.12% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 43.86% |
| Owned by Institutions (%) | 49.75% |
| Float | 176.62M |
Valuation Ratios
The trailing PE ratio is 53.77 and the forward PE ratio is 11.94.
| PE Ratio | 53.77 |
| Forward PE | 11.94 |
| PS Ratio | 1.23 |
| Forward PS | 1.16 |
| PB Ratio | 624.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.43 |
| P/OCF Ratio | 10.95 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.51, with an EV/FCF ratio of 25.40.
| EV / Earnings | 85.00 |
| EV / Sales | 2.03 |
| EV / EBITDA | 9.51 |
| EV / EBIT | 14.56 |
| EV / FCF | 25.40 |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 450.96.
| Current Ratio | 2.17 |
| Quick Ratio | 1.39 |
| Debt / Equity | 450.96 |
| Debt / EBITDA | 4.06 |
| Debt / FCF | 11.15 |
| Interest Coverage | 1.74 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 7.32% |
| Return on Invested Capital (ROIC) | 15.95% |
| Return on Capital Employed (ROCE) | 15.04% |
| Weighted Average Cost of Capital (WACC) | 10.06% |
| Revenue Per Employee | $346,984 |
| Profits Per Employee | $8,282 |
| Employee Count | 8,700 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 3.10 |
Taxes
In the past 12 months, AMRX has paid $11.28 million in taxes.
| Income Tax | 11.28M |
| Effective Tax Rate | 8.10% |
Stock Price Statistics
The stock price has increased by +35.51% in the last 52 weeks. The beta is 1.30, so AMRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | +35.51% |
| 50-Day Moving Average | 13.66 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 29.05 |
| Average Volume (20 Days) | 2,359,583 |
Short Selling Information
The latest short interest is 9.92 million, so 3.15% of the outstanding shares have been sold short.
| Short Interest | 9.92M |
| Short Previous Month | 10.60M |
| Short % of Shares Out | 3.15% |
| Short % of Float | 5.62% |
| Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, AMRX had revenue of $3.02 billion and earned $72.06 million in profits. Earnings per share was $0.22.
| Revenue | 3.02B |
| Gross Profit | 1.13B |
| Operating Income | 420.70M |
| Pretax Income | 139.21M |
| Net Income | 72.06M |
| EBITDA | 644.27M |
| EBIT | 420.70M |
| Earnings Per Share (EPS) | $0.22 |
Full Income StatementBalance Sheet
The company has $286.47 million in cash and $2.69 billion in debt, with a net cash position of -$2.40 billion or -$7.64 per share.
| Cash & Cash Equivalents | 286.47M |
| Total Debt | 2.69B |
| Net Cash | -2.40B |
| Net Cash Per Share | -$7.64 |
| Equity (Book Value) | 5.96M |
| Book Value Per Share | -0.23 |
| Working Capital | 1.03B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $339.99 million and capital expenditures -$98.84 million, giving a free cash flow of $241.15 million.
| Operating Cash Flow | 339.99M |
| Capital Expenditures | -98.84M |
| Depreciation & Amortization | 223.57M |
| Net Borrowing | 107.61M |
| Free Cash Flow | 241.15M |
| FCF Per Share | $0.77 |
Full Cash Flow StatementMargins
Gross margin is 37.38%, with operating and profit margins of 13.94% and 2.39%.
| Gross Margin | 37.38% |
| Operating Margin | 13.94% |
| Pretax Margin | 4.61% |
| Profit Margin | 2.39% |
| EBITDA Margin | 21.34% |
| EBIT Margin | 13.94% |
| FCF Margin | 7.99% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.12% |
| Shareholder Yield | -5.12% |
| Earnings Yield | 1.94% |
| FCF Yield | 6.48% |
Analyst Forecast
The average price target for AMRX is $14.75, which is 24.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.75 |
| Price Target Difference | 24.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 1.8 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 7 |
